-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Downgrades Haemonetics to Outperform, Lowers Price Target to $78

Benzinga·08/11/2025 11:23:24
Listen to the news
Raymond James analyst Andrew Cooper downgrades Haemonetics (NYSE:HAE) from Strong Buy to Outperform and lowers the price target from $105 to $78.